<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04709835</url>
  </required_header>
  <id_info>
    <org_study_id>WV43042</org_study_id>
    <nct_id>NCT04709835</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19</brief_title>
  <official_title>A Phase II Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Antiviral Activity, Safety, Pharmacokinetics, and Efficacy of RO7496998 (AT-527) in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Atea Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized study evaluates the antiviral activity, safety, efficacy and pharmacokinetics&#xD;
      of AT-527 versus a placebo in participants with mild or moderate coronavirus disease&#xD;
      (COVID-19) who are not hospitalized.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 3, 2021</start_date>
  <completion_date type="Actual">October 13, 2021</completion_date>
  <primary_completion_date type="Actual">September 17, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in the Amount of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Virus RNA</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>SARS-CoV-2 virus RNA will be measured by reverse-transcription polymerase chain reaction (RT-PCR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Cessation of SARS-CoV-2 Viral Shedding</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>Time to cessation of viral shedding is defined as the time between the initiation of any study treatment and first time when the virus RNA by RT-PCR is below the limit of detection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Sustained Non-Detectable SARS-CoV-2 Virus RNA</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>Time to sustained non-detectable SARS-CoV-2 virus RNA is defined as the time from initiation of study treatment to the last timepoint when the virus RNA by RT-PCR is below the limit of detection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants Positive for SARS-CoV-2 Virus RNA at Specified Timepoints</measure>
    <time_frame>Up to Day 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve (AUC) in the Amount of SARS-CoV-2 Virus RNA</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>AUC in the amount of SARS-CoV-2 virus RNA from baseline to the last sample timepoint.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation or Improvement of COVID-19 Symptoms (21.5 hours)</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>Alleviation of symptoms is defined as the length of time taken from start of treatment to the point at which a Score of 0 or 1 has been maintained for a duration of at least 21.5 hours. Improvement of symptoms is defined as at least a single category improvement from baseline on the Likert scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation or Improvement of COVID-19 Symptoms (43 hours)</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>Alleviation of symptoms is defined as the length of time taken from start of treatment to the point at which a Score of 0 or 1 has been maintained for a duration of at least 43 hours. Improvement of symptoms is defined as at least a single category improvement from baseline on the Likert scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation of COVID-19 Symptoms (21.5 hours)</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>Alleviation of symptoms is defined as the length of time taken from start of treatment to the point at which the following criteria are met and maintained for at least 21.5 hours: Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary (without consideration for presence of pre-existing symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation of COVID-19 Symptoms (43 hours)</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>Alleviation of symptoms is defined as the length of time taken from start of treatment to the point at which the following criteria are met and maintained for at least 43 hours: Score of 0 or 1 on Items 1-12 of the COVID-19 Symptom Diary (without consideration for presence of pre-existing symptoms).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Fever</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>Defined as the time to return to an afebrile state (temperature ≤ 37.5°C) maintained for at least 21.5 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of COVID-19 Related Complications</measure>
    <time_frame>Up to 33 Days</time_frame>
    <description>Examples of COVID-19 related complications include death, hospitalization, radiologically confirmed pneumonia, acute respiratory failure, sepsis, coagulopathy, pericarditis, myocarditis, and cardiac failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Alleviation of an Individual Symptom</measure>
    <time_frame>Up to 28 Days</time_frame>
    <description>Time to alleviation of an individual symptom is defined as the time taken from the start of treatment to the point at which the following criterion is met and maintained (for each individual symptom) for at least 21.5 hours:&#xD;
Score of 0 or 1 for Items 1-12 of the COVID-19 Symptom Diary.&#xD;
Score of 0 for Items 13 and 14 of the COVID-19 Symptom Diary.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants with Adverse Events (AEs)</measure>
    <time_frame>Up to 33 Days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of AT-511, AT-551, AT-229 and AT-273</measure>
    <time_frame>Up to Day 7</time_frame>
    <description>AT-511 is the free base form of AT-527. Its major metabolites are AT-551, AT-229, and AT 273.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">104</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>AT-527</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive 550 mg AT-527 twice a day (BID) in Cohort A and 1100 mg AT-527 BID in Cohort B.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AT-527</intervention_name>
    <description>Results from Cohort A determined the dose and regimen to be used for Cohort B.</description>
    <arm_group_label>AT-527</arm_group_label>
    <other_name>RO7496998</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The dose and regimen of the placebo will match that of the respective AT-527 comparator arm.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Positive SARS-CoV-2 diagnostic test (RT-PCR or rapid antigen test)at screening&#xD;
&#xD;
          -  Has symptoms consistent with mild or moderate COVID-19, as determined by the&#xD;
             investigator, with onset ≤5 days prior to randomization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Clinical signs indicative of COVID-19 illness requiring hospitalization, defined as&#xD;
             any of the following: shortness of breath at rest, respiratory rate ≥30, heart rate&#xD;
             ≥125, peripheral capillary oxygen saturation ≤93% on room air&#xD;
&#xD;
          -  Treatment with a therapeutic agent against SARS-CoV-2 including, but not limited to,&#xD;
             other direct acting antivirals, convalescent plasma, monoclonal antibodies against&#xD;
             SARS CoV-2, or intravenous immunoglobulin within 3 months or less than 5 drug&#xD;
             elimination half-lives (whichever is longer) prior to screening&#xD;
&#xD;
          -  Requirement, in the opinion of the investigator, for any of the prohibited medications&#xD;
             during the study&#xD;
&#xD;
          -  Use of hydroxychloroquine or amiodarone within 3 months of screening&#xD;
&#xD;
          -  Pregnant or breastfeeding, or intending to become pregnant during the study or within&#xD;
             30 days after the final dose of AT-527. Women of childbearing potential must have a&#xD;
             negative urine pregnancy test result at screening&#xD;
&#xD;
          -  Abnormal laboratory test results at screening&#xD;
&#xD;
          -  Clinically significant abnormal ECG, as determined by the Investigator, at screening&#xD;
&#xD;
          -  Planned procedure or surgery during the study&#xD;
&#xD;
          -  Known allergy or hypersensitivity to study drug or drug product excipients&#xD;
&#xD;
          -  Substance abuse, as determined by the investigator, within 12 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Poor peripheral venous access&#xD;
&#xD;
          -  Malabsorption syndrome or other condition that would interfere with enteral absorption&#xD;
&#xD;
          -  Any clinically significant history of epistaxis within the last 3 months and/or&#xD;
             history of being hospitalized due to epistaxis of any previous occasion&#xD;
&#xD;
          -  History of anaphylaxis&#xD;
&#xD;
          -  Any uncontrolled serious medical condition or other clinically significant abnormality&#xD;
             in clinical laboratory tests that, in the investigator's judgment, precludes the&#xD;
             patient's safe participation in and completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Puls AD PPDS</name>
      <address>
        <city>Blagoevgrad</city>
        <zip>2700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital For Active Treatment Dr. Tota Venkova JSC</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Dr. Atanas Dafovski AD</name>
      <address>
        <city>Kardzhali</city>
        <zip>6600</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Prof. Dr. Paraskev Stoyanov AD</name>
      <address>
        <city>Lovech</city>
        <zip>5500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical center Medconsult Pleven OOD</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Multiprofile Hospital for Active Treatment Sveta Marina Pleven OOD</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment Plovdiv</name>
      <address>
        <city>Plovdiv</city>
        <zip>4003</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Sv. Ivan Rilski&quot; - Razgrad AD; Department of pnemology and phthisiatry</name>
      <address>
        <city>Razgrad</city>
        <zip>7200</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specialized Hospital for Active Treatment of Pneumophthisiatric Diseases Dr. D. Gramatikov - Ruse</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment - Samokov EOOD</name>
      <address>
        <city>Samokov</city>
        <zip>2000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic and Consulting Center Aleksandrovska EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Consultative CTR XX Sofia EOOD</name>
      <address>
        <city>Sofia</city>
        <zip>1618</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Multiprofile Hospital for Active Treatment (MHAT) - Targovishte</name>
      <address>
        <city>Targovishte</city>
        <zip>7700</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver Infectious Diseases Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 2C7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hamilton Medical Research Group</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8M 1K7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelismos General Hospital of Athens</name>
      <address>
        <city>Athens</city>
        <zip>106 76</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sotiria General Hospital of Athens; 3rd Department of Internal Medicine</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National and Kapodistrian University of Athens</name>
      <address>
        <city>Athens</city>
        <zip>115 28</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Ioannina</name>
      <address>
        <city>Ioannina</city>
        <zip>455 00</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>General State Hospital of Nikaia St Panteleimon</name>
      <address>
        <city>Nikaia Attikis</city>
        <zip>184 54</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Connolly Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>15</zip>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice of Dr Liga Kozlovska</name>
      <address>
        <city>Balvi</city>
        <zip>LV-4501</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RSU Ambulance</name>
      <address>
        <city>Riga</city>
        <zip>LV-1007</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Outpatient Clinic Alma</name>
      <address>
        <city>Rīga</city>
        <zip>LV-1010</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Outpatient Clinic Adoria</name>
      <address>
        <city>Rīga</city>
        <zip>LV-1011</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Family Physician's Practice of Dr. Maija Kozlovska</name>
      <address>
        <city>Salaspils</city>
        <zip>LV-2121</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M &amp; M Centrs</name>
      <address>
        <city>Ādaži</city>
        <zip>LV-2164</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UAB Inmedica</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-48259</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JSC Saules Family Health Center</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-4949</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vilnius University Hospital Santaros Klinikos</name>
      <address>
        <city>Vilnius</city>
        <zip>8406</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krakowskie Centrum Medyczne Sp. z o.o.</name>
      <address>
        <city>Krakow</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Pulawska SP. z o.o.</name>
      <address>
        <city>Piaseczno</city>
        <zip>05-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Klinicznty MSWiA w Warszawie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badań Klinicznych</name>
      <address>
        <city>Wrocław</city>
        <zip>51-162</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital El Pilar - Grupo Quirónsalud</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <state>Barcelona</state>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Son Espases</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <zip>07010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Costa del Sol</name>
      <address>
        <city>Marbella</city>
        <state>Malaga</state>
        <zip>29600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Paz - PPDS</name>
      <address>
        <city>Barcelona</city>
        <zip>8041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Infanta Leonor</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chapel Street Medical Centre</name>
      <address>
        <city>Ashton-under-Lyne</city>
        <zip>OL6 6EW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tower Family Healthcare - Moorgate Primary Care Ce</name>
      <address>
        <city>Bury</city>
        <zip>BL9 0NJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPS Research</name>
      <address>
        <city>Glasgow</city>
        <zip>G20 0XA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelsea and Westminster NHS Trust</name>
      <address>
        <city>London</city>
        <zip>SW3 6JJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Greece</country>
    <country>Ireland</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 12, 2021</study_first_submitted>
  <study_first_submitted_qc>January 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 14, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm)</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

